

Special Issue

New Findings in Targeting Cancer Proteins (Second Edition)

Message from the Guest Editors

This Special Issue is a continuation of our previous one, entitled 'New Findings in Targeting Cancer Proteins'. Recent advances in targeting cancer proteins have also highlighted the crucial role of cellular metabolism in supporting tumor growth and survival. Cancer cells often rewire their metabolic pathways—such as glycolysis, glutaminolysis, and lipid metabolism—to meet their elevated energy and biosynthesis demands. Targeting these metabolic dependencies offers a promising therapeutic avenue, especially when combined with inhibitors of oncogenic signaling pathways. Emerging evidence suggests that metabolic enzymes can act as both regulators and effectors of cancer-driving proteins, making them attractive targets for precision therapy. In the Special Issue 'New Findings in Targeting Cancer Proteins (Second Edition)', we aim to collect original articles and reviews presenting data on the newest findings in the field of protein-targeted cancer therapy, which currently holds the best promise for developing more effective and personalized treatment approaches.

Guest Editors

Dr. Maristella Maggi

Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy

Dr. Claudia Scotti

Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy

Deadline for manuscript submissions

30 November 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/238282

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)